Research status and progress of oncolytic virus in the treatment of bladder cancer

doi:10.3877/cma.j.issn.2095-5820.2025.02.007

Abstract

Abstract:

Bladder cancer remains the most prevalent malignant tumor in the urinary system.Current treatment strategies are primarily determined by tumor invasiveness. Non-muscle-invasive bladder cancer (NMIBC) typically undergoes transurethral resection with adjuvant intravesical therapy, while muscle-invasive urothelial carcinoma (MIBC) requires radical cystectomy. However, both approaches face significant challenges with disease recurrence. Recent advances in cancer molecular biology, immunology, and genetics have revealed the therapeutic potential of oncolytic viruses, with promising efficacy demonstrated in preclinical bladder cancer models. This emerging modality offers novel treatment opportunities for bladder cancer management. This review comprehensively examines the current research status and recent progress in oncolytic virotherapy for bladder cancer, highlighting its potential to address the limitations of conventional treatments.

Key words: bladder cancer, intravesical therapy, oncolytic virus

Jinlong Chen, Xiaodong Guan. Research status and progress of oncolytic virus in the treatment of bladder cancer[J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2025, 13(02): 106-110.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcsysgldzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5820.2025.02.007

https://zhlcsysgldzzz.cma-cmc.com.cn/EN/Y2025/V13/I02/106

References 30

1	BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: A cancer journal for clinicians,2024, 74(3): 229-263.
2	SIEGEL R L, GIAQUINTO A N, JEMAL A. Cancer statistics, 2024[J].CA: A cancer journal for clinicians, 2024, 74(1): 12-49.
3	ABBAS N F, AOUDE M R, KOURIE H R, et al. Uncovering the epidemiology of bladder cancer in the Arab world: A review of risk factors, molecular mechanisms, and clinical features[J]. Asian journal of urology, 2024, 11(3): 406-422.
4	ANTONI S, FERLAY J, SOERJOMATARAM I, et al. Bladder cancer incidence and mortality: A global overview and recent trends[J].European urology, 2017, 71(1): 96-108.
5	韩苏军, 张思维, 陈万青, 等. 中国膀胱癌发病现状及流行趋势分析[J]. 癌症进展, 2013, 11(1): 89-95.
6	SYLVESTER R J, OOSTERLINCK W, HOLMANG S, et al.Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: Which patients benefit from the instillation?[J]. European urology, 2016, 69(2): 231-244.
7	于浩, 林天歆, 李响, 等. 卡介苗预防中、高危非肌层浸润性膀胱癌术后复发的有效性、安全性随机、对照、多中心临床试验中期报告[J]. 中华泌尿外科杂志, 2019, 40(7): 485-491.
8	孙颖浩. 吴阶平泌尿外科学[M]. 北京：人民卫生出版社, 2019:1236.
9	WANG L, CHARD D L S, CHENG Z, et al. Remodeling the tumor microenvironment by oncolytic viruses: Beyond oncolysis of tumor cells for cancer treatment[J]. Journal for immunotherapy of cancer,2022,10(5): e004167.
10	GRANDI P, DARILEK A, MOSCU A, et al. Intravesical infusion of oncolytic virus CG0070 in the treatment of bladder cancer[J]. Methods in molecular biology, 2023, 2684: 303-317.
11	BURKE J M, LAMM D L, MENG M V, et al. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer[J]. The journal of urology, 2012, 188(6): 2391-2397.
12	PACKIAM V T, LAMM D L, BAROCAS D A, et al. An open label,single-arm, phase Ⅱ multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results[J]. Urologic oncology, 2018, 36(10): 440-447.
13	GLASS M, BUSCHE A, WAGNER K, et al. Conditional and reversible disruption of essential herpesvirus proteins[J]. Nature methods, 2009, 6(8): 577-579.
14	JOO K J, LI H, ZHANG X, et al. Therapeutic effect on bladder cancer with a conditionally replicating oncolytic virus derived from type Ⅱherpes simplex virus[J]. Bladder cancer, 2015, 1(1): 81-90.
15	CZERNIAK B, COHEN G L, ETKIND P, et al. Concurrent mutations of coding and regulatory sequences of the Ha-ras gene in urinary bladder carcinomas[J]. Human pathology, 1992, 23(11): 1199-1204.
16	KOHNO S, LUO C, GOSHIMA F, et al. Herpes simplex virus type 1 mutant HF10 oncolytic viral therapy for bladder cancer[J]. Urology,2005, 66(5): 1116-1121.
17	SHMULEVITZ M, MARCATO P, LEE P W. Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer[J]. Oncogene, 2005, 24(52): 7720-7728.
18	GUMMERSHEIMER S L, SNYDER A J, DANTHI P. Control of capsid transformations during reovirus entry[J]. Viruses, 2021, 13(2):153.
19	HANEL E G, XIAO Z, WONG K K, et al. A novel intravesical therapy for superficial bladder cancer in an orthotopic model: Oncolytic reovirus therapy[J]. The journal of urology, 2004, 172(5 Pt 1): 2018-2022.
20	LIM Y, PARK J, LIM J E, et al. Evaluating a combination treatment of NK cells and reovirus against bladder cancer cells using an in vitro assay to simulate intravesical therapy[J]. Scientific reports, 2024,14(1): 7390.
21	MELL L K, BRUMUND K T, DANIELS G A, et al. Phase Ⅰ trial of intravenous oncolytic vaccinia virus (GL-ONC1) with cisplatin and radiotherapy in patients with locoregionally advanced head and neck carcinoma[J]. Clinical cancer research: An official journal of the American Association for Cancer Research, 2017, 23(19): 5696-5702.
22	PARK S H, BREITBACH C J, LEE J, et al. Phase 1b trial of biweekly intravenous Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus in colorectal cancer[J]. Molecular therapy: The journal of the American Society of Gene Therapy, 2015, 23(9): 1532-1540.
23	GOMELLA L G, MASTRANGELO M J, MCCUE P A, et al. PhaseⅠ study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer[J]. The journal of urology, 2001, 166(4): 1291-1295.
24	POTTS K G, IRWIN C R, FAVIS N A, et al. Deletion of F4L(ribonucleotide reductase) in vaccinia virus produces a selective oncolytic virus and promotes anti-tumor immunity with superior safety in bladder cancer models[J]. EMBO molecular medicine, 2017, 9(5):638-654.
25	SHAFREN D R, AU G G, NGUYEN T, et al. Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, Coxsackievirus a21[J]. Clinical cancer research: An official journal of the American Association for Cancer Research,2004, 10(1 Pt 1): 53-60.
26	AU G G, LINDBERG A M, BARRY R D, et al. Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21[J].International journal of oncology, 2005, 26(6): 1471-1476.
27	BERRY L J, AU G G, BARRY R D, et al. Potent oncolytic activity of human enteroviruses against human prostate cancer[J]. The prostate,2008, 68(6): 577-587.
28	SKELDING K A, BARRY R D, SHAFREN D R. Systemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21[J]. Breast cancer research and treatment, 2009, 113(1): 21-30.
29	AU G G, LINCZ L F, ENNO A, et al. Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma[J]. British journal of haematology, 2007, 137(2): 133-141.
30	RELPH K, ANNELS N, SMITH C, et al. Oncolytic immunotherapy for bladder cancer using Coxsackie A21 virus: Using a bladder tumor precision-cut slice model system to assess viral efficacy[J]. Methods in molecular biology, 2020, 2058: 249-259.

[1]	Wenhao Zhan, Ren Liu, Xiaolan Zeng, Junxing Chen, Zongren Wang. Comparison of transurethral en-bloc resection and transurethral resection of bladder tumor for the treatment of high-risk non-muscle-invasive bladder cancer [J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(03): 309-314.
[2]	Yunkai Qie, Zhe Zhang, Shan Liang, Zhouliang Wu, Yuzhu Li, Chenghui Fu, Chong Shen, Hailong Hu. The value of transurethral en-bloc resection of bladder tumor in pathological sub-staging of T1 stage bladder cancer [J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(03): 303-308.
[3]	Hong Zeng. Interpretation of commonly used immunohistochemical markers in pathological reports of bladder cancer [J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(03): 296-302.
[4]	Haixia He, Shoumin Bai. The utilization of radiotherapy in bladder-sparing treatment for muscle-invasive bladder cancer and the refinement of strategies to minimize toxicity [J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(03): 288-295.
[5]	Shiwang Huang, Yunkai Qie, Hailong Hu. Application of artificial intelligence in non-invasive urine-based diagnostic methods for bladder cancer [J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(03): 283-287.
[6]	Junhao Liao, Lilin Zhou, Jianwen Zeng. Multidisciplinary consultation on difficult cases in Guangdong Urological Association （Phase 25）： pelvic recurrence of bladder cancer after radical cystectomy [J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(03): 390-394.
[7]	Qing Xue, Saiye Shi, Yawen Xu, Xia Sheng, Qinqin Zhang. Application of tracking methodology combined with failure mode and effect analysis in patients with bladder perfusion chemotherapy [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(06): 553-559.
[8]	Mingyang Pang, Yong Wei, Luming Shen, Qingyi Zhu. Domestic single port robot-assisted laparoscopic partial cystectomy via pneumatic bladder approach for bladder cancer: a case report [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(06): 638-643.
[9]	Minimally Invasive Surgery Professional Committee of the Chinese Research Hospital Association The, Intelligent Medicine Professional Committee of the Chinese Research Hospital Association The. Expert consensus on robotic radical resection for gallbladder cancer [J]. Chinese Journal of Laparoscopic Surgery(Electronic Edition), 2025, 18(02): 78-82.
[10]	Botao Chen, Kuan Hu, Xianhai Mao. Tumor microenvironment and systematic treatment of gallbladder cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(02): 203-208.
[11]	Qingguang Liu, Zhimin Geng, Dong Zhang, Qi Li. Current status and thinking of minimally invasive radical cholecystectomy for gallbladder cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(02): 158-166.
[12]	Kecan Lin, Liuping Luo. Key problems in the application of hepatopancreaticoduodenectomy for gallbladder cancer and cholangiocarcinoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 774-778.
[13]	Dawen Zheng, Jiandong Wang. Research progress in adjuvant diagnosis of gallbladder cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 769-773.
[14]	Weijie Chen, Xiaodong He. Progress in immunotargeted therapy for gallbladder cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 763-768.
[15]	Hongsheng Ji, Wanqing Wei, Jianguo Qiu, Liucheng Wang, Fujin Jiang, Xianyun Zhang, Sugui Wang. Expression of KPNB1 in bladder cancer and its role in proliferation and migration of bladder cancer cells [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(11): 1044-1053.

Please choose a citation manager

Content to export